Chimeric Clarifies ASX Query on CORE NK Trial Disclosures

The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).

Chimeric Therapeutics has submitted a revised response to an ASX query regarding disclosure of results from its ADVENT-AML Phase 1b trial using its CHM CORE NK technology, after ASX directed the company to update and clarify its earlier November 2025 response. The company emphasised the distinction between two separate CORE NK clinical trials, noting that a prior October 2024 announcement of a complete response related to the Combination trial, not the ADVENT-AML study.

In the revised response, Chimeric removed a misattributed reference, detailed the exact timing of when it became aware of key clinical information, and explained why a single CRi MRD-positive outcome in one of six dose-escalation patients was not considered materially price sensitive. It also reiterated that, as the trials are investigator-sponsored, it relies on the external sponsor for data updates and outlined how it assessed and met its disclosure obligations under ASX Listing Rules.

The clarifications aim to address ASX concerns over the company’s handling of market-sensitive trial data and to reinforce confidence in its compliance and governance around clinical disclosure. These steps may help reassure investors about the robustness of Chimeric’s reporting practices as it continues to progress its CHM CORE NK clinical programs.

The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Ltd. is an Australian clinical-stage biotechnology company focused on developing cell-based immunotherapies, including its CHM CORE NK technology, for the treatment of cancers such as acute myeloid leukaemia. The company is listed on the ASX under the ticker CHM and advances its programs through multiple early-stage clinical trials in collaboration with external sponsors.

Technical Sentiment Signal: Sell

Current Market Cap: A$11.05M

Learn more about CHM stock on TipRanks’ Stock Analysis page.